IL-1β signaling on dendritic cells expands tumor-specific T cells to overcome immune checkpoint blockade resistance.
Immune checkpoint blockade (ICB) therapy benefits only a subset of patients, and the role of non-T cells in ICB responses remains unclear. IL-1β has been reported to conduct controversial roles in antitumor immunity and ICB responsiveness. Here we show that IL-1β signaling is indispensable for the response to ICB thera...